Cargando…

Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine

BACKGROUND: Glioblastoma (GBM) develops resistance to the advances in chemotherapy leading to poor prognosis and life quality. Consequently, new treatment modalities are needed. Our aims were to investigate the effects of combined noscapine (NOS) and imatinib mesylate (IM) on human GBM in vitro and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Erguven, Mine, Bilir, Ayhan, Yazihan, Nuray, Ermis, Ezgi, Sabanci, Akin, Aktas, Esin, Aras, Yavuz, Alpman, Vehbi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3135492/ https://www.ncbi.nlm.nih.gov/pubmed/21651812 http://dx.doi.org/10.1186/1475-2867-11-18

Ejemplares similares

Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro
por: Bilir, Ayhan, et al.
Publicado: (2011)

Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer
por: Taja-Chayeb, Lucia, et al.
Publicado: (2006)

Nerium oleander Distillate Improves Fat and Glucose Metabolism in High-Fat Diet-Fed Streptozotocin-Induced Diabetic Rats
por: Bas, Ahmet Levent, et al.
Publicado: (2012)

MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia
por: Rabello, Doralina do Amaral, et al.
Publicado: (2018)

Serum midkine level might be a diagnostic tool for COVID19 disease in pregnancy: From the disease severity, hospitalization and disease progression respects
por: Yazihan, Nuray, et al.
Publicado: (2022)

Periorbital edema secondary to imatinib mesylate
por: McClelland, Collin M, et al.
Publicado: (2010)

Cutaneous adverse effects of imatinib mesylate
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2015)

Suramin Increased Telomerase Activity in the C6 Glioma/Wistar Experimental Brain Tumor Model
por: Ergüven, Mine, et al.
Publicado: (2007)

Midkine promotes glioblastoma progression via PI3K-Akt signaling
por: Hu, Beiquan, et al.
Publicado: (2021)

Imatinib Mesylate-Induced Hyperpigmentation of the Nose and Palate
por: Song, Hyo Sang, et al.
Publicado: (2014)

Imatinib mesylate resistance and mutations: An Indian experience
por: Srivastava, Shweta, et al.
Publicado: (2013)

Lichenoid drug eruption due to imatinib mesylate
por: Bhatia, Anuradha, et al.
Publicado: (2015)

The teratogenic effects of imatinib mesylate on rat fetuses
por: El Gendy, M.M., et al.
Publicado: (2015)

Exacerbation of Psoriasis after Imatinib Mesylate Treatment
por: Shim, Joon Ho, et al.
Publicado: (2016)

Role of ATP-dependent K channels in the effects of erythropoietin in renal ischaemia injury
por: Yilmaz, Tonguç Utku, et al.
Publicado: (2015)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

The role of c-kit and imatinib mesylate in uveal melanoma
por: Pereira, Patricia Rusa, et al.
Publicado: (2005)

Plantar Keratoderma with Pachyonychia Likely Induced by Imatinib Mesylate
por: Kim, Hyung Ok, et al.
Publicado: (2013)

Ageing is a risk factor in imatinib mesylate cardiotoxicity
por: Maharsy, Wael, et al.
Publicado: (2014)

Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate
por: Karolewicz, Bożena, et al.
Publicado: (2019)

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate
por: Pautier, Patricia, et al.
Publicado: (2013)

Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib
por: Lee, Min Kyung, et al.
Publicado: (2015)

Phase II trial of imatinib mesylate in patients with metastatic melanoma
por: Kim, K B, et al.
Publicado: (2008)

Metastatic duodenal GIST: role of surgery combined with imatinib mesylate
por: Mohiuddin, Kamran, et al.
Publicado: (2007)

ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
por: Rink, Lori, et al.
Publicado: (2013)

Generalized Lichenoid Drug Eruption Associated with Imatinib Mesylate Therapy
por: Ghosh, Sudip Kumar
Publicado: (2013)

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010)

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)

Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™)
por: Cho, Ah Young, et al.
Publicado: (2011)

In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells
por: Weigel, Marion T, et al.
Publicado: (2010)

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
por: Gauden, Ruth, et al.
Publicado: (2011)

Imatinib Mesylate-Induced Cutaneous Rash Masquerading as Pityriasis Rosea of Gilbert
por: Verma, Prashant, et al.
Publicado: (2014)

Complete pathological response to Imatinib mesylate in an extraintestinal gastrointestinal stromal tumor
por: Quezada, Nicolás, et al.
Publicado: (2014)

Lichenoid Drug Eruption after Low-Dose Imatinib Mesylate Treatment
por: Lee, Jae-Hyung, et al.
Publicado: (2013)

Effects of imatinib mesylate on pulmonary allergic vasculitis in a murine model
por: Suzuki, Naomi, et al.
Publicado: (2013)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia
por: Vieira-Mion, Ana Lucia, et al.
Publicado: (2017)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017)

Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1
por: Yasuda, Ken‐ichi, et al.
Publicado: (2020)

Kaposi’s sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy
por: D’Addona, Matteo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3sk5k11ihk5qqstmopfq853ced